CLINICAL TRIALS PROFILE FOR ENASIDENIB MESYLATE
✉ Email this page to a colleague
All Clinical Trials for enasidenib mesylate
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT03683433 ↗ | Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation | Unknown status | National Cancer Institute (NCI) | Phase 2 | 2018-09-18 | This phase II trial studies how well enasidenib and azacitidine work in treating patients with IDH2 gene mutation and acute myeloid leukemia that has come back (recurrent) or does not respond to treatment (refractory). Enasidenib and azacitidine may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. |
| NCT03683433 ↗ | Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation | Unknown status | M.D. Anderson Cancer Center | Phase 2 | 2018-09-18 | This phase II trial studies how well enasidenib and azacitidine work in treating patients with IDH2 gene mutation and acute myeloid leukemia that has come back (recurrent) or does not respond to treatment (refractory). Enasidenib and azacitidine may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. |
| NCT03728335 ↗ | Enasidenib as Maintenance Therapy in Treating Patients With Acute Myeloid Leukemia With IDH2 Mutation After Donor Stem Cell Transplant | Recruiting | National Cancer Institute (NCI) | Phase 1 | 2019-07-11 | This phase I trial studies the side effects of using enasidenib as maintenance therapy in treating patients with acute myeloid leukemia with IDH2 mutation following donor stem cell transplant. Enasidenib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. |
| NCT03728335 ↗ | Enasidenib as Maintenance Therapy in Treating Patients With Acute Myeloid Leukemia With IDH2 Mutation After Donor Stem Cell Transplant | Recruiting | City of Hope Medical Center | Phase 1 | 2019-07-11 | This phase I trial studies the side effects of using enasidenib as maintenance therapy in treating patients with acute myeloid leukemia with IDH2 mutation following donor stem cell transplant. Enasidenib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. |
| NCT03825796 ↗ | CPX-351 Plus Enasidenib for Relapsed AML | Suspended | Jazz Pharmaceuticals | Phase 2 | 2019-04-12 | This trial evaluates how well CPX-351 and enasidenib work in treating patients with acute myeloid leukemia characterized by IHD2 mutation. Drugs used in chemotherapy, such as CPX-351, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Enasidenib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving CPX-351 and enasidenib may work better in treating patients with acute myeloid leukemia, compared to giving only one of these therapies alone. |
| NCT03825796 ↗ | CPX-351 Plus Enasidenib for Relapsed AML | Suspended | National Cancer Institute (NCI) | Phase 2 | 2019-04-12 | This trial evaluates how well CPX-351 and enasidenib work in treating patients with acute myeloid leukemia characterized by IHD2 mutation. Drugs used in chemotherapy, such as CPX-351, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Enasidenib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving CPX-351 and enasidenib may work better in treating patients with acute myeloid leukemia, compared to giving only one of these therapies alone. |
| NCT03825796 ↗ | CPX-351 Plus Enasidenib for Relapsed AML | Suspended | Jonsson Comprehensive Cancer Center | Phase 2 | 2019-04-12 | This trial evaluates how well CPX-351 and enasidenib work in treating patients with acute myeloid leukemia characterized by IHD2 mutation. Drugs used in chemotherapy, such as CPX-351, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Enasidenib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving CPX-351 and enasidenib may work better in treating patients with acute myeloid leukemia, compared to giving only one of these therapies alone. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for enasidenib mesylate
Condition Name
| Condition Name for enasidenib mesylate | |
| Intervention | Trials |
| Recurrent Acute Myeloid Leukemia | 5 |
| IDH2 Gene Mutation | 3 |
| Refractory Acute Myeloid Leukemia | 3 |
| Allogeneic Hematopoietic Stem Cell Transplantation Recipient | 1 |
| [disabled in preview] | 0 |
| This preview shows a limited data set Subscribe for full access, or try a Trial | |
Clinical Trial Locations for enasidenib mesylate
Trials by Country
Clinical Trial Progress for enasidenib mesylate
Clinical Trial Phase
Clinical Trial Sponsors for enasidenib mesylate
Sponsor Name
